The pathogenesis of polycystic ovary syndrome: Lessons from ovarian stimulation studies

被引:27
作者
Barnes, RB [1 ]
机构
[1] Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA
关键词
polycystic ovary syndrome; functional ovarian hyperandrogenism; theca cell; granulosa cell;
D O I
10.1007/BF03350782
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In polycystic ovary syndrome (PCOS) the ovary produces markedly increased amounts of both androgens and estrogens in response to gonadotropin stimulation. Distinctive responses of 17-hydroxyprogesterone and androstenedione to ovarian stimulation testing suggest that ovarian hyperandrogenism is a result of dysregulation of theca cell androgen production which is intrinsic to the ovary. The occurrence of hyperestrogenism together with hyperandrogenism in PCOS suggests that whatever the abnormality of local regulatory factors of steroidogenesis, it affects granulosa as well as theca cells. Dysregulation is often associated with an increase in the number of follicles which evade atresia and reach the 2-8 mm stage of development. Autocrine/paracrine factors, especially those which are FSH-dependent, likely play an important role in the pathogenesis of the ovarian abnormality. Both LH and insulin hypersecretion probably play a secondary role in PCOS by amplifying the preexisting ovarian dysregulation. Because FSH secretion is under tight long-loop negative-feedback control and LH is not, hyperandrogenism is the primary clinical manifestation of dysregulation of steroid production in PCOS. However, anovulation in PCOS is most likely a result of excessive estrogen and inhibin production by multiple, small follicles which inhibit FSH secretory dynamics sufficiently to prevent selection of a dominant follicle. (J. Endocrinol. Invest. 21: 567-579, 1998) (C) 1998, Editrice Kurtis.
引用
收藏
页码:567 / 579
页数:13
相关论文
共 94 条
[11]   The android woman - A risky condition [J].
Bjorntorp, P .
JOURNAL OF INTERNAL MEDICINE, 1996, 239 (02) :105-110
[12]   INSULIN RESISTANCE IN NON-OBESE PATIENTS WITH POLYCYSTIC OVARIAN DISEASE [J].
CHANG, RJ ;
NAKAMURA, RM ;
JUDD, HL ;
KAPLAN, SA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 57 (02) :356-359
[13]  
Cheung AP, 1997, HUM REPROD, V12, P1156
[14]   HOW COMMON ARE POLYCYSTIC OVARIES IN NORMAL WOMEN AND WHAT IS THEIR SIGNIFICANCE FOR THE FERTILITY OF THE POPULATION [J].
CLAYTON, RN ;
OGDEN, V ;
HODGKINSON, J ;
WORSWICK, L ;
RODIN, DA ;
DYER, S ;
MEADE, TW .
CLINICAL ENDOCRINOLOGY, 1992, 37 (02) :127-134
[15]  
DANIELS TL, J CLIN ENDOCRINOL ME, V82, P4179
[16]   Hormonal effects of flutamide in young women with polycystic ovary syndrome [J].
De Leo, V ;
Lanzetta, D ;
D'Antona, D ;
la Marca, A ;
Morgante, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (01) :99-102
[17]   EXCESSIVE INSULIN-RECEPTOR SERINE PHOSPHORYLATION IN CULTURED FIBROBLASTS AND IN SKELETAL-MUSCLE - A POTENTIAL MECHANISM FOR INSULIN-RESISTANCE IN THE POLYCYSTIC-OVARY-SYNDROME [J].
DUNAIF, A ;
XIA, JR ;
BOOK, CB ;
SCHENKER, E ;
TANG, ZC .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (02) :801-810
[18]   PROFOUND PERIPHERAL INSULIN RESISTANCE, INDEPENDENT OF OBESITY, IN POLYCYSTIC OVARY SYNDROME [J].
DUNAIF, A ;
SEGAL, KR ;
FUTTERWEIT, W ;
DOBRJANSKY, A .
DIABETES, 1989, 38 (09) :1165-1174
[19]   Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis [J].
Dunaif, A .
ENDOCRINE REVIEWS, 1997, 18 (06) :774-800
[20]   The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome [J].
Dunaif, A ;
Scott, D ;
Finegood, D ;
Quintana, B ;
Whitcomb, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (09) :3299-3306